Published in Leuk Lymphoma on June 01, 1995
Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule. Br J Cancer (1997) 0.82
CNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV). BMC Infect Dis (2005) 0.80
High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin. Toxins (Basel) (2016) 0.76
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med (1998) 4.39
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Foreign-body perforation of the intestinal tract. Report of 12 cases and review of the literature. Arch Surg (1970) 3.26
Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol (1999) 2.14
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Symptoms, anxiety and handicap in dizzy patients: development of the vertigo symptom scale. J Psychosom Res (1992) 2.07
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia. J Clin Oncol (1999) 1.87
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1999) 1.69
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
Review of small bowel obstruction at Milwaukee County General Hospital. Am J Surg (1966) 1.56
Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol (2001) 1.56
Purification and partial characterization of the antiviral protein from Phytolacca americana which inhibits eukaryotic protein synthesis. Arch Biochem Biophys (1975) 1.56
Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. Cell Death Differ (2006) 1.55
Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies. Nature (1990) 1.54
Determination of viability of ischemic intestine by Doppler ultrasound. Surgery (1978) 1.54
Bypass grafting to distal arteries for limb salvage. Surg Gynecol Obstet (1972) 1.54
Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther (1994) 1.51
Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther (1992) 1.51
Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics (1996) 1.50
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest (1996) 1.49
Diabetes in prison: can good diabetic care be achieved? BMJ (1992) 1.49
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia (2000) 1.48
Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol (1994) 1.48
Childhood acute lymphoblastic leukaemia--current status and future perspectives. Lancet Oncol (2001) 1.48
Cardiovascular risk factors in patients with peripheral vascular disease. Surgery (1978) 1.44
Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med (1990) 1.44
The effect of an antiviral peptide on the ribosomal reactions of the peptide elongation enzymes, EF-I and EF-II. Arch Biochem Biophys (1973) 1.44
Acute suppurative cholangitis. Experience with 15 consecutive cases. Arch Surg (1967) 1.43
Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer (1997) 1.42
Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. J Clin Oncol (1991) 1.42
Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer (1997) 1.41
Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet (1999) 1.40
Purification and properties of a second antiviral protein from Phytolacca americana which inactivates eukaryotic ribosomes. Arch Biochem Biophys (1980) 1.40
Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). J Clin Oncol (2000) 1.38
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2000) 1.37
Inhibition of poliovirus replication by a plant antiviral peptide. Ann N Y Acad Sci (1977) 1.37
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A (1995) 1.36
Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem (1999) 1.35
ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia (2010) 1.34
The effects of "cell age" upon the lethal effects of physical and chemical mutagens in the yeast, Saccharomyces cerevisiae. Mol Gen Genet (1976) 1.34
Enalapril worldwide experience. Am J Med (1984) 1.33
A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet (1995) 1.33
Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res (1999) 1.32
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem (1996) 1.32
Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet (1998) 1.31
Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet (1993) 1.29
Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood (1994) 1.29
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest (1994) 1.29
Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood (1995) 1.29
Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clin Pharmacol Ther (1982) 1.28
Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol (2000) 1.28
Blind river dolphin: first side-swimming cetacean. Science (1969) 1.25
Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood (1996) 1.24
Inhibition of herpes simplex virus multiplication by the pokeweed antiviral protein. Antimicrob Agents Chemother (1980) 1.24
Purification and partial characterization of another form of the antiviral protein from the seeds of Phytolacca americana L. (pokeweed). Biochem J (1982) 1.24
Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A (1997) 1.23
Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol (1997) 1.23
Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group. Leukemia (2004) 1.23
Expression of dominant-negative Ikaros isoforms in T-cell acute lymphoblastic leukemia. Clin Cancer Res (1999) 1.23
Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet (2000) 1.21
O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab (2010) 1.20
Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood (1997) 1.18
Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19. Proc Natl Acad Sci U S A (1988) 1.18
Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem (2001) 1.18
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia (1997) 1.18
Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett (2001) 1.17
Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol (1995) 1.15
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther (2010) 1.15
The effect of renal function on enalapril kinetics. Clin Pharmacol Ther (1985) 1.15
Nonparasitic splenic cysts. Case report of epidermoid cyst with review of the literature. Am J Surg (1973) 1.14
Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia (1998) 1.14
Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol (1996) 1.14